bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1712762
Sentiment: neutral
Topics: material-agreement, financials, filing
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on Sept 2, 2025, likely a material agreement or financials. Watch for details.
AI Summary
On September 2, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also includes financial statements and exhibits. Specific details of the agreement or financial performance were not provided in this excerpt.
Why It Matters
This filing signals a significant event for bioAffinity Technologies, Inc., potentially involving a new material agreement or updated financial information that could impact investors.
Risk Assessment
Risk Level: medium — An 8-K filing often contains material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- September 2, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41463 (identifier) — Commission File Number
- 46-5211056 (identifier) — I.R.S. Employer Identification Number
- 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by bioAffinity Technologies, Inc. on September 2, 2025?
The provided excerpt does not specify the details of the material definitive agreement.
What specific financial statements are included in this 8-K filing?
The excerpt states that financial statements are included, but does not list their specific content or period.
What is the principal business of bioAffinity Technologies, Inc. according to the filing?
The filing lists the Standard Industrial Classification as SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731].
Where are bioAffinity Technologies, Inc.'s principal executive offices located?
The principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
What is the filing date for this 8-K report?
The report was filed as of September 2, 2025.
Filing Stats: 641 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2025-09-02 09:29:58
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
- $0.10 — 025 Warrants) so as to increase it from $0.10 to $0.15. As a result, the total number
- $0.15 — nts) so as to increase it from $0.10 to $0.15. As a result, the total number of share
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex4-1.htm (EX-4.1) — 26KB
- ex4-2.htm (EX-4.2) — 24KB
- 0001641172-25-026168.txt ( ) — 313KB
- biaf-20250902.xsd (EX-101.SCH) — 4KB
- biaf-20250902_def.xml (EX-101.DEF) — 26KB
- biaf-20250902_lab.xml (EX-101.LAB) — 36KB
- biaf-20250902_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 2, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-